

### SIOPEN Flash News 8

#### Contents

- 1. Welcome
- 2. Key points of the last EC meeting
- 3. Contact

### Issue n°8 – February 2021

Dear SIOPEN members,

We are happy to provide you with the 8th SIOPEN Flash news. Key points:

- SIOPE meeting draft programme
- EUSA Pilot study discussions
- SIOPEN Finance Steering Group
- Follow-up Registry
- Strategic Group Meeting later in 2021

Best wishes, Maja Beck Popovic, SIOPEN President



### SIOPEN Flash News 8

#### **Contents**

- 1. Welcome
- 2. Key points of the last EC meeting
- 3. Contact

#### **SIOPE** meeting:

- SIOPE will meet from 28-30 April 2021 (remotely).
- Draft programme available:
- https://www.czech-in.org/cmPortalv15/Searchable/siope20/config/nodetails#!sessionschedule
- SIOPEN meeting is planned for Friday 30<sup>th</sup> April 2021.

### **EUSA Pilot study on immunotherapy in induction:**

 After temporary suspension of the Pilot study by EUSA for regulatory purposes in November 2020, the discussion has been reactivated, as CHMP has confirmed the need of investigating dinutuximab beta in the current SIOPEN induction treatments. Modifications of the current Pilot study are under discussion between EUSA and the writing committee in order to have a time and cost efficient and scientifically valid study. The planned participating centers will be contacted in due time.





#### **Contents**

- 1. Welcome
- 2. Key points of the last EC meeting
- 3. Contact

# SIOPEN Flash News 8

#### **SIOPEN Finance Steering Group:**

- A finance steering committee proposal has been drafted and being reviewed by EC&AB.
- This committee has the task to review SIOPEN capacity to fund research projects validated by the clinical trial committee and EC&AB, before final sign-off by the SIOPEN treasurer and president.
- Currently 6 members are proposed for the committee, including a charity representative.

#### Follow-up registry:

- E&AB have approved the Quality of Life and Long Term Outcome Committee to develop a proposal for a follow-up registry.
- This is needed for patients not recruited to SIOPEN clinical trials and when trials close to continued data collection.
- Registry consent, transition and re-consent and other regulatory and logistical considerations will require careful review.



#### **Contents**

- 1. Welcome
- 2. Key points of the last EC meeting
- 3. Contact

# SIOPEN Flash News 8

#### **SIOPEN Strategic Group Meeting:**

- SIOPEN needs to review long-term strategy and priorities
- EC&AB gives support for a SIOPEN large group strategic meeting (hopefully face to face) later in 2021, similar to other tumour groups and ITCC.
- Committee chairs and national deputies will be requested to submit potential topics, themes and priorities for discussion to enable the EC&AB to draft meeting agenda and select relevant speakers.



# SIOPEN Flash News 6

#### **Contents**

- 1. Welcome
- 2. Key points of the last EC meeting
- 3. Contact

#### **Contacts**



SIOPEN members website <a href="http://members.siopen.org/">http://members.siopen.org/</a>
SIOPEN public website <a href="https://www.siopen.net/">https://www.siopen.net/</a>



SIOPEN President 

<u>maja.beck-popovic@chuv.ch</u>

Assistant of SIOPEN president 

<u>elena.lemmel@chuv.ch</u>

SIOPEN Vice-presidents: Lucas Moreno and Shifra Ash

<u>lucas.moreno@vhebron.net</u>

<u>s\_ash@rambam.health.gov.il</u>